Arcutis Biotherapeutics, Inc. Operating Income Loss

Quick Answer

Arcutis Biotherapeutics, Inc. reported Operating Income Loss of -$12.23 million for the year ending 2025.

  • Arcutis Biotherapeutics, Inc. showed an increase of +90.5% in Operating Income Loss from 2024 to 2025.
  • This data is from Arcutis Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), Arcutis Biotherapeutics, Inc.'s Operating Income Loss has grown by 38.0%.
  • Historical annual values: Fiscal year 2025: -$12.23 million | Fiscal year 2024: -$128.40 million | Fiscal year 2023: -$241.10 million | Fiscal year 2022: -$301.63 million | Fiscal year 2021: -$206.53 million | Fiscal year 2020: -$136.65 million | Fiscal year 2019: -$43.13 million | Fiscal year 2018: -$19.74 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: